We describe two patients belonging to distinct Cowden disease families each associated with a germline PTEN mutation whose phenotypes mimicked Proteus syndrome. A secondary molecular event in one ...
BURLINGTON, Mass.-- (BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results